Fig. 4.

Relapse-free survival and overall survival according to the FOXA1 and/or FOXP1 immunoreactivities in the patients with tamoxifen-treated breast cancer with or without distant metastasis within 5 years after surgery or entire follow-up period (n = 113). The Kaplan–Meier survival curves were plotted using JMP 9 software, and the statistical significances were determined using the log-rank test. a, b Patients with the positive FOXA1 immunoreactivity showed good relapse-free survival and overall survival (a and b, respectively). c, d Relapse-free survival and overall survival according to the FOXP1 immunoreactivity in the patients with tamoxifen-treated breast cancer with or without distant metastasis within 5 years after surgery or entire follow-up period. Patients with positive FOXP1 immunoreactivity showed good relapse-free survival and overall survival (c and d, respectively). e, f Patients with double-positive FOXA1 and FOXP1 immunoreactivities showed better relapse-free survival and overall survival (e and f, respectively)